DATA GRAPHICS | Data Byte
Clinical BCMA antibody therapies behind Tecvayli
EC’s approval of Tecvayli establishes bispecifics as a modality for the target
September 26, 2022 8:32 PM UTC
At least 10 antibody-based therapies targeting BCMA are coming up behind Tecvayli in clinical development for cancer. All of them are in testing for multiple myeloma, Tecvayli’s approved indication, and six products incorporate a CD3-binding arm to engage T cells, as the J&J therapy does.
In August, the European Commission conditionally approved Tecvayli teclistamab, a BCMA X CD3 bispecific antibody from Johnson & Johnson (NYSE:JNJ), to treat multiple myeloma (MM) patients who have received at least three prior lines of therapy. ...